Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors

• Published in: Therapeutic Advances in Musculoskeletal Disease Vol. 12; p. 1759720X20930116
• Main Authors: Evangelatos, Gerasimos, Koulouri, Vasiliki, Iliopoulos, Alexios, Fragoulis, George E
• Format: Book Review Journal Article
• Language: English
• Published: London, England SAGE Publications 2020; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Biological products; Drugs; Immunotherapy; Monoclonal antibodies; Necrosis; Precision medicine; Targeted cancer therapy; Tuberculosis; Tumor necrosis factor-TNF; When Rheumatology and Infectious Disease Come Together; targeted synthetic DMARDs; Tumor necrosis factor inhibitor; biologic DMARDs; rheumatic disease; autoimmune; tuberculosis

Patients with autoimmune rheumatic diseases (ARD) have an increased risk for tuberculosis (TB). The use of tumor necrosis factor inhibitors (TNFi) and glucocorticoids in these patients has been associated with an increased prevalence of latent TB reactivation. Over the last few years, several biolog...